Cargando…

The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy

Herpes Zoster (HZ) presents a considerable public health burden in Italy among people aged ≥50 years. This study aimed to assess the clinical and economic impact of HZ vaccination in the 65 years of age (YOA) cohort in Italy, by comparing the new Adjuvanted Recombinant Zoster Vaccine (RZV) with the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Volpi, Antonio, Boccalini, Sara, Dari, Silvia, Clarke, Christopher, Curran, Desmond, Loiacono, Idalba, Pitrelli, Andrea, Puggina, Anna, Tosatto, Roberta, Van Oorschot, Desirée, Franco, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062451/ https://www.ncbi.nlm.nih.gov/pubmed/31442095 http://dx.doi.org/10.1080/21645515.2019.1657753

Ejemplares similares

The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy
por: Matthews, Sean, et al.
Publicado: (2019)

Meta-Regression of Herpes Zoster Incidence Worldwide
por: Curran, Desmond, et al.
Publicado: (2021)

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany
por: Curran, Desmond, et al.
Publicado: (2017)

A systematic literature review of herpes zoster incidence worldwide
por: van Oorschot, Désirée, et al.
Publicado: (2021)

1440. Meta-regression Analysis of Worldwide Herpes Zoster Incidence
por: Yawn, Barbara P, et al.
Publicado: (2021)

Lowering the recommended age for the free and active offer of influenza vaccination in Italy: clinical and economic impact analysis in the Liguria region
por: Trucchi, Cecilia, et al.
Publicado: (2020)

Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older
por: Shiragami, Makoto, et al.
Publicado: (2019)

The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis
por: Watanabe, Daisuke, et al.
Publicado: (2018)

A Cross-Sectional Concept Elicitation Study to Understand the Impact of Herpes Zoster on Patients’ Health-Related Quality of Life
por: Van Oorschot, Desirée, et al.
Publicado: (2022)

Healthy ageing: Herpes zoster infection and the role of zoster vaccination
por: Curran, Desmond, et al.
Publicado: (2023)

Assessment of the Potential Herpes Zoster and Post Herpetic Neuralgia Case Avoidance with Vaccination in the United States
por: Patterson, Brandon J, et al.
Publicado: (2017)

The temporal impact of aging on the burden of herpes zoster
por: Varghese, Lijoy, et al.
Publicado: (2017)

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
por: Giannelos, Nikolaos, et al.
Publicado: (2023)

Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany
por: Curran, Desmond, et al.
Publicado: (2021)

Return on Investment (ROI) of Three Vaccination Programmes in Italy: HPV at 12 Years, Herpes Zoster in Adults, and Influenza in the Elderly
por: Barbieri, Marco, et al.
Publicado: (2023)

Estimated Public Health Impact of the Recombinant Zoster Vaccine
por: Patterson, Brandon J., et al.
Publicado: (2021)

Compliance with herpes zoster vaccination in young and adult individuals in two regions of Italy
por: Parlato, Antonino, et al.
Publicado: (2010)

Herpes Zoster: the rationale for the introduction of vaccination in Italy
por: PAGANINO, C., et al.
Publicado: (2015)

Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme
por: van Oorschot, Desirée A M, et al.
Publicado: (2019)

Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
por: McGirr, Ashleigh, et al.
Publicado: (2019)

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer
por: Curran, Desmond, et al.
Publicado: (2023)

Lifetime risk of herpes zoster in the population of Beijing, China
por: Lee, Christa, et al.
Publicado: (2023)

Herpes Zoster and Recurrent Herpes Zoster
por: Shiraki, Kimiyasu, et al.
Publicado: (2017)

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
por: Curran, Desmond, et al.
Publicado: (2019)

Herpes zoster ophthalmicus or Herpes zoster maxillaris?
por: Chandravanshi, Shivcharan Lal, et al.
Publicado: (2009)

Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old
por: Van Oorschot, Desirée, et al.
Publicado: (2018)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2021)

Incidence of herpes zoster and post-herpetic neuralgia in Italy: Results from a 3-years population-based study
por: Alicino, Cristiano, et al.
Publicado: (2016)

Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above
por: Curran, Desmond, et al.
Publicado: (2018)

2300. Incidence, Complications, and Recurrence of Herpes Zoster in Unvaccinated Adults ≥50 Years of Age
por: Ackerson, Bradley, et al.
Publicado: (2019)

Herpes Zoster
por: Warneros Loyo, María de Lourdes
Publicado: (1995)

Herpes Zoster
Publicado: (1890)

Herpes Zoster
por: Wile, Henry
Publicado: (1886)

Natural History of Herpes Zoster in the Placebo Groups of Three Randomized Phase III Clinical Trials
por: Curran, Desmond, et al.
Publicado: (2022)

Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based study
por: Gialloreti, Leonardo Emberti, et al.
Publicado: (2010)

Modeled impact of the COVID-19 pandemic and associated reduction in adult vaccinations on herpes zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2022)

7. Can Recombinant Zoster Vaccine Administration Decrease the Use of Herpes Zoster-related Pain Medication Across Randomized Controlled Studies?
por: Kim, Joon Hyung, et al.
Publicado: (2020)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Herpes Zoster / Revisión Bibliográfica /
por: Escamilla Sánchez, Jacqueline
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_7m83huvena848lvffvoft79ljl